Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 685-281-3 | CAS number: 2624-17-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Experimental results from repeated dose studies by the oral route (59 day, 13 week (according to OECD guideline 408) and 104 weeks (according to EU Method B.33) on sodium cyanurate monohydrate or sodium cyanurate.
Read-across from a 13-week study with cyanuric acid.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study performed to GLP and equivalent to guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EU Method B.33 (Combined Chronic Toxicity / Carcinogenicity Test)
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- other: Charles River CD
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc. Portage, Michigan, USA
- Age at study initiation: ~5 weeks old
- Weight at study initiation: males: 87.0-164.0 g; females 72.0 – 141.0 g
- Housing: Suspended wire mesh cages
- Diet: Provided ad libitum
- Water: Provided ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°F): 71
- Humidity (%): 59-61
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: drinking water
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: The appropriate amount of test material was dissolved in tap water and mixed using a motor driven propeller. The pH of the testing solutions was adjusted to pH 7.4 using glacial acetic acid and/or sodium hydroxide. Fresh drinking water solutions were prepared 3 times weekly.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of drinking water from all groups were analysed on days 1, 3, 5 and of weeks 1 through 15 and on day 1 of weeks 16 through 106
- Duration of treatment / exposure:
- 104 weeks
- Frequency of treatment:
- ad libitum / continuous
- Remarks:
- Doses / Concentrations:
0, 400 ppm, 1200 ppm, 2400 ppm, 5375 ppm (males ~ 25, 76, 154, 371 mg/kg bw/d; females ~ 42, 129, 266, 634 mg/kg bw/d).
Basis: - No. of animals per sex per dose:
- Low dose group: 80/sex
Mid dose, mid-high dose and high dose groups: 100/sex/dose level
Tap water control: 100/sex
Sodium control: 80/sex - Control animals:
- other: Vehicle (tap water), Sodium control (sodium hippurate)
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Weekly
BODY WEIGHT: Yes
- Time schedule for examinations: Recorded weekly during the pretest and first 14 weeks of the study, every 2 weeks thereafter
FOOD CONSUMPTION: Yes
- Time schedule for examinations: recorded weekly for the first 14 weeks of the study, every 2 weeks thereafter
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: Weekly
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: 6, 12, 18 and 24 months
- Anaesthetic used for blood collection: No data
- Animals fasted: Yes
- How many animals: 10 rats/sex
- Parameters checked: Total and differential leukocyte count, erythrocyte count, haemoglobin, haematocrit, platelet count, reticulocyte count, haematological indices mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCH).
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: 6, 12, 18 and 24 months
- Animals fasted: Yes
- How many animals: 10 rats/sex
- Parameters checked: Sodium, potassium, chloride, calcium, phosphorous, osmolality, alkaline phosphatase, total bilirubin, aspartate aminotransferase, alanine aminotransferase, lactic dehydrogenase, blood urea nitrogen, creatinine, total protein, albumin, globulin (calculated), cholesterol and glucose.
URINALYSIS: Yes
- Time schedule for collection of urine: 6, 12, 18 and 24 months
- Metabolism cages used for collection of urine: No
- Animals fasted: Yes
- Parameters checked: Colour and appearance, microscopic examination of sediment, volume, osmolality, pH, protein, glucose, occult blood, nitrites, bilirubin, ketones, urobilinogen, sodium, potassium, chloride, magnesium, phosphorous, calcium, urea nitrogen, creatinine
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes all animals received a complete post mortem.
Organs: external examination; contents of the abdominal, thoracic and cranial cavities were examined both in situ and after removal and dissection. Adrenal, all gross lesions, all tissue masses, brain (fore-, mid-, and hind-), cecum, colon, duodenum, esophagus, eye and contiguous Harderian gland, heart with coronary vessels, ileum, jejunum, kidneys, liver (3 sections) lung and mainstream bronchi, lymph nodes (medistinal, mesenteric and regional), mammary gland, ovaries, pancreas, peripheral nerve (sciatic), pituitary, prostate / corpus and cervix uteri, mandibular salivary gland, skeletal thigh muscle, skin, spinal cord (cervical and thoracic), spleen, sternum bone marrow, stomach, testis with epididymus, thymus, thyroid and parathyroid, tongue, trachea, ureter, urinary bladder, whole head (including nasal, oral and otic tissue) and Zymbal’s gland.
HISTOPATHOLOGY: Yes a full tissue compliment was prepared for all animals in control and high dosage groups. Sections of the following organs from animals in the 400 ppm, 1200 ppm, 2400 ppm groups sacrificed at 6, 12and 18 months and all animals which died or were sacrificed in extremis between 0 and 24 months of study: adrenal, heart, kidneys, liver, ovaries, spleen, testes, ureter, urinary bladder, tissue masses and gross lesions. Gross lesions and tissue masses were microscopically examined for animals in the 400 ppm, 1200 ppm, 2400 ppm dose groups which survived to terminal sacrifice - Statistics:
- Body weights and food consumption (weekly for weeks 1 – 4, quarterly thereafter) organ weights, (absolute and relative to body weights, interim and terminal sacrifices) clinical laboratory values (6, 12, 18 and 24 months prior to interim and terminal sacrifices) were analysed by Bartlett’s test for homogeneity of variance and analysis of variance (one-way classification). Treatment groups were compared to the control group and to the sodium control group by sex, using the appropriate t-statistic (equal or unequal variance) as described by Steel and Torrie and Ostle. Dunnett’s multiple comparison tables were used to determine significance. All statistical tests were two-tailed. Survival data and data on time to neoplastic lesion were analysed using the computer program of Thomas, Breslow and Gart. Statistical procedures included in this program are the Kaplan-Meier and standard methods for computing survival curves, Cox’s test for linear trend in proportions and both Cox’s test and Gehan-Breslow’s generalized Kruskall-Wallis test for comparing survival distributions. Data on time to neoplastic lesion were analysed for all benign tumors, all malignant tumors, all tumors combined and for individual type that appeared in two or more animals in the high dose group
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
Red urine was observed for 5375 ppm group males (week 1 – 62) and appeared to be test article related and correlated with the high incidence of urinary bladder calculi. Decreased defecation and / or no faeces occurred more frequently for 5375 ppm group males (week 1 – 62) and a slightly higher incidence of yellow material (anogenital region, ventral surface, ventral abdomen, hindlimb) for 2400 and 5375 ppm female groups (weeks 14 – 39) and for male rats in the 5375 ppm group (weeks 1 – 52). In weeks 14 – 52 some male rats in the 5375 ppm group were noted to feel cold to the touch.
Survival was a little lower for high dose males (5375 ppm) as compared to control animals in weeks 26 – 104. Females given 1200 ppm and 2400 ppmhad a lower survival rate at 104 weeks compared to control animals
BODY WEIGHT AND WEIGHT GAIN:
Male control and treatment withdrawal rats were similar in weeks 63 – 104. The body weight of the withdrawal rats was also similar to their respective male groups not placed on compound withdrawal. Group mean body weights of female rats receiving 2400 and 5375 ppm after withdrawal were higher compared to group mean body weights of female control withdrawal animals and non withdrawal females receiving 2400 and 5375 ppm
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
Group mean food consumption values for both males and females were similar in all groups including the untreated controls. Overall. the with drawal animals in all groups consumed more food (g/rat/day) during the recovery period than the animals in the main study.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
Water consumption of male and female treatment groups and the sodium control group was higher than those of the control group. The increased water consumption appeared dose related. No definite trend in water consumption of the compound withdrawal group was evident. Average water consumption (weeks 63 – 104) of male and female 2400 ppm and 5375 ppm withdrawal groups was higher than those of male and female control groups during the recovery period. Male and female 5375 ppm withdrawal groups showed decreased average water consumption as compared to non withdrawal male and female 5375 ppm groups in weeks 63 – 104
HAEMATOLOGY
No significant treatment related effects were observed.
CLINICAL CHEMISTRY
No results of pathologic significance were observed
URINALYSIS
No significant treatment related effects were observed
ORGAN WEIGHTS
There were no test article related organ weight variations in the treatment groups at any of the interim or terminal sacrifices
GROSS PATHOLOGY
Calculi in the kidney (pelvis) or urinary bladder, hydronephrosis, hydroureter, blood in urine and distention of urinary bladder were test article related in male rats from the 5375 ppm group sacrificed at the 6 month interim, died / sacrificed in extremis during the 0 – 12 month period of the study. Urolithiasis was the primary lesion. None of the rats at 12, 18 or 24 months or any rat that died / sacrificed in extremis during the 12 – 24 month periods showed any test article effects.
HISTOPATHOLOGY: NON-NEOPLASTIC
No evidence of a test article related carcinogenic effect was observed in any tissues or organs examined microscopically from male or female rats from any of the experimental groups. A non neoplastic change of questionable toxicological significance occurred in the kidneys of a small number of female rats from the 5375 ppm group which died or were sacrificed in extremis during the period 6 – 12 months.
Urinary tract lesions were probably related to the presence of urinary tract calculi. These lesions included hyperplasia of the urinary bladder epithelium, acute cystitis and hemorrhage in the bladder wall, which correlated with macroscopic observations of bladder calculi. Almost all test article related urinary tract lesions were limited to male rats from the 5375 ppm group which died, were sacrificed in extremis or were electively sacrificed in the first 12 months of study with most occurring in animals which died or were sacrificed in extremis. Hydroureter was sometimes associated with bladder calculi, some dilated ureters were also inflamed and hemorrhagic. Test article related kidney lesions consisted of tubular nephrosis in some rats from the 5375 ppm group which died or were sacrificed in extremis during the period 6 - 12 months. Calculi were noted in the bladders of some affected males, no calculi were found in any of the affected females. Test article related urinary tract lesions only occurring in the first 12 months of study suggests that some males by the nature of their urinary tract structure were more prone to obstruction and succumbed early. Occurrence of bladder epithelial hyperplasia and associated test article related bladder lesions in rats which did not have grossly evident calculi is consistent with a calculus based mechanism. Calculi which were transiently present but which were small enough to pass on the urine stream would cause irritation during their residence in the bladder. Uremia due to urinary tract obstruction by calculi was the probable cause of death in animals in which calculi could not be passed.
Heart lesions in 5375 ppm males which died or were sacrificed in extremis during the first 12 months of study also had urinary bladder calculi and or distention at necroscopy suggesting that the heart lesions were of uremic etiology, secondary to urinary tract obstruction.
An increased incidence of splenic hemosiderosis in male rats of the 5375 ppm group was possibly test article related but did not correlate with any alteration in clinical pathologic parameters.
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 154 mg/kg bw/day (nominal)
- Sex:
- male
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 266 mg/kg bw/day (nominal)
- Sex:
- female
- Dose descriptor:
- LOAEL
- Effect level:
- ca. 371 mg/kg bw/day (nominal)
- Sex:
- male
- Dose descriptor:
- LOAEL
- Effect level:
- ca. 634 mg/kg bw/day (nominal)
- Sex:
- female
- Critical effects observed:
- not specified
- Executive summary:
Sodium cyanurate was administered in the drinking water in a two year toxicity and oncogenicity study in rats. Non-neoplastic lesions were observed in urinary tracts of males in the 5375 ppm group sacrificed at the 6 and 12 month interims. Heart and urinary tract lesions occurred in 5375 ppm males which died or were sacrificed in extremis during the first 12 months of the study. The only possible substance related changes in females were in the urinary tract of the 5375 ppm animals which died or were sacrificed in extremis during the 6 – 12 month period of study. In the 18 month interim sacrifice and the 24 month terminal sacrifice no lesions were detected which could be attributed to treatment with the test article.
No evidence of test article related carcinogenic effect was observed in any tissues or organs examined microscopically from male or female rats of any test group.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 154 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- Study performed to GLP and equivalent to guideline (Klimisch 1).
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral Exposure:
1. Experimental results obtained with the substance monosodium salt of cyanuric acid (LOAEL > 4000 ppm and NOAEL = 4000 ppm).
Read-across: 2. Based on the experimental results obtained with the analogue cyanuric acid (NOAEL ca.231 mg/kg bw/day male; NOAEL ca. 914 mg/kg bw/day female; LOAEL ca. 109 mg/kg bw/day male; LOAEL ca. 915 mg/kg bw/day female), the read-across approach is applied and the NOAEL and LOAEL for substance sodium cyanurate are calculated to be NOAEL ca 272 mg/kg bw/day male; NOAEL ca. 1076 mg/kg bw/day female; LOAEL ca. 128 mg/kg bw/day male; LOAEL ca. 1078 mg/kg bw/day female under test conditions.
3. Experimental results obtained with the substance monosodium salt of cyanuric acid, monohydrate (NOAEL = 5375 ppm and LOAEL < 5375 ppm).
4. Experimental results obtained with the substance monosodium salt of cyanuric acid, monohydrate (Rat: NOAEL ca. 154 mg/kg bw/day, male; NOAEL ca. 266 mg/kg bw/day, female; LOAEL ca. 371 mg/kg bw/day, male; LOAEL ca. 634 mg/kg bw/day, female).
5. Experimental results obtained with the substance monosodium salt of cyanuric acid (Mouse: NOAEL ca. 1523 mg/kg bw/day, male and NOAEL ca. 1582 mg/kg bw/day, female).
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Chronic data is available (rats and mice). The NOAEL value obtained in the study with rats is considered for the effect level (lowest NOAEL).
Justification for classification or non-classification
No systemic toxicological findings could be detected after repeated administration of sodium cyanurate by the oral route.Therefore, a classification as STOT RE is not justified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.